Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X about a recent article by E. Quandt et al, published in JAMA Oncology:
“ICI-Induced Diabetes: Rare but Severe Analysis of ~14,000 patients in NCI trials shows 0.5% incidence, higher with combination immunotherapy, lower with chemotherapy.
Most cases require hospitalization, some ICU.
Vigilant glucose monitoring and early detection are essential in ICI-treated patients.”
Title: Immune Checkpoint Inhibitor–Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents
Authors: E. Quandt, Shanda Finnigan, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Darah Davidson, Abdul Rafeh Naqash, Mark S. Anderson, Megan Othus, Elad Sharon, Elad Sharon, Megan Othus
Read the full article on JAMA Oncology.
More posts featuring Aya Mohamed on OncoDaily.